DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas

Genes Chromosomes and Cancer

Volumn 25, Issue 1, 1999, Pages 16-25

  Wu, Chu Lee ^a   Roz, Luca ^b   McKown, Susan ^c   Sloan, Philip ^c   Read, Andrew P ^a   Holland, Susan ^c   Porter, Stephen ^b   Scully, Crispian ^b   Paterson, Ian ^d   Tavassoli, Mahavash ^e   Thakker, Nalin ^a,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENE PRODUCT; PROTEIN;

ALLELE; ARTICLE; CHROMOSOME 9P; CONTROLLED STUDY; GENE; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METHYLATION; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0012894628     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2264(199905)25:1<16::aid-gcc3>3.0.co;2-2     Document Type: Article

References (39)

1. Ah-See KW, Cooke TG, Pickford IR, Soutar D, Balmain A. 1994. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res 54:1617-1621.
2. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho K R, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D. 1995. Frequency of homozygous deletion at CDKN2A/CDKN2 in primary human tumors. Nature Genet 11:210-212.
3. Califano J, Ahrendr SA, Meininger G, Westra WH, Koch WM, Sidransky D. 1996. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res 56:5720-5722.
4. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun K, Lathrop M, Gyapay G, Morissette J, Weissenbach J. 1996. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 380:152-154.
5. El-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V. 1995. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 55:2656-2659.
6. Farrell WE, Simpson DJ, Bicknell JF, Talbot AJ, Bates AS and Clayton RN. 1997. Chromosome 9p deletions in invasive and non-invasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 57:2703-2709.
7. Flores JF, Walker, GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP. Pastorfide GC, Boyer LA, Kao WH, Bulyk ML, Barnhill RL, Hayward NK, Housman DE, Fountain JW. 1996. Loss of the CDKN2AINK4a and p151NK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56:5023-5032.
8. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 55:6006-6011.
9. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, BEart RW, Van Tornout JM, Jones PA. 1995. Methylation of the 5′ CpG island of the CDKN2A/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535.
10. Haber DA. 1997. Splicing into senescence: the curious case of CDKN2A and p19ARF. Cell 91:555-558.
11. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. 1995. Inactivation of the CDKN2/ CDKN2A/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
12. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. 1994. Germline CDKN2A mutations in familial melanoma. Nat Genet 8:15-21.
13. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran, T, Miki Y, Weaver-Feldhaus J, MeClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright L. 1994. Analysis of the CDKN2A gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:22-26.
14. Kiaris, H, Spanakis, N, Ergazaki, M, Sourvinos, G, Spandidos, DA. 1995. Loss of heterozygosity at 9p and 17p in human laryngeal tumors. Cancer Lett 97:129-134.
15. Kim SK, Ro JY, Kemp BL, Lee JS, Kwon TJ, Fong KM, Sedido Y, Minna JD, Hong WK, Mao L. 1997. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res 57:400-403.
16. Macfarlane GJ, Boyle P, Scully C. 1992. Oral cancer in Scotland: changing incidence and mortality. Brit Med J 305:1121-1123.
17. Maefarlane GJ, Boyle P, Evstifeeva TV, Robertson C, Scully C. 1994. Rising trends of oral cancer mortality among males worldwide: the return of an old public health problem. Cancer Causes Control 5:259-265.
18. Mead LJ, Gillespie MT, Hung JY, Rane US, Rayeroux KC, Irving LB, Campbell LJ. 1992. Frequent loss of heterozygosity in early non-small cell lung cancers at chromosome 9p21 proximal to the CDKN2A gene. Int J Cancer 71:213-217.
19. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 1995. 5' CpG island methylation is associated with transeriptional silencing of the tumor suppressor CDKN2A/CDKN2/MTS1 in human cancers. Nature Med 1:686-692.
20. Nawroz H, van der Riet PM, Hruban RH, Koch W, Ruppert JM, Sidransky D. 1994. Allelotype of head and neck squamous cell carcinoma. Cancer Res 54:1152-1155.
21. Neville EM, Stewart M, Myskow M, Donnelly RJ, Field JK. 1995. Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene 11:581-585.
22. Okamoto, A, Demetrick D, Spillare E, Hagiwara K, Hussain S, Bennett W, Forrester K, Gerwin B, Serrano M, Beach D, Harris C. 1994. Mutations and altered expression of CDKN2AINK4 in human cancer. Proc Nat Acad Sci USA 91:11045-11049.
23. Parkin DM, Pisani P, Ferlay J. 1993. Estimates of world-wide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606.
24. Patel V, Yeudall A, Gardner A, Mutlu S, Scully C, Prime SS. 1993. Consistent chromosomal abnormalities in keratinocyte cell lines derived from untreated malignant lesions of the oral cavity. Genes Chromosomes Cancer 7:109-115.
25. Pollock PM, Pearson JV, Hayward NK. 1996. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 15:77-88.
26. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. 1998. The Ink4a tumor suppressor gene product. p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
27. Prime SS, Nixon SVR, Crane IJ, Stone A, Matthews JB, Maitland NJ, Remnant L, Powell SK, Game SM, Scully C. 1990. The behaviour of human oral squamous cell carcinoma in cell culture. J Pathol 160:259-269.
28. Puig S, Ruiz A, Lazaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM, Estivill X. 1995. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet 57:395-402.
29. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D. 1996. High frequency of CDKN2A (CDKN2/MTS-1/1NK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633.
30. Roz L, Wu CL, Porter S, Scully C, Speight P, Read A, Sloan P, Thakker NS. 1996. Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res 56:1228-1231.
31. Spruek CH III, Gonzalez-Zuleta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA. 1994. CDKN2A gene in uncultured tumors. Nature 370:183-184.
32. van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D. 1994. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54:1156-1158.
33. Van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, Wolf GT, Drumheller T, Tilley BC, Carey TE. 1994. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck. Genes Chromosomes Cancer 9:192-206.
34. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
35. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. 1995. p16(CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4:1569-1577.
36. Wu CL, Sloan P, Read AP, Harris RH, Thakker NS. 1994. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res 54:6484-6488.
37. Wu CL, Roz L, Sloan P, Read A, Holland S, Porter S, Scully C, Speight P, Thakker NS. 1997. Deletion mapping defines three discrete areas of allelic imbalance on chromosome 8p in oral and oropharyngeal squamous cell carcinomas. Genes Chromosomes Cancer 20:347-353.
38. Wu CL, Thakker NS, Neary W, Black G, Lye R, Ramsden RT, Read AP, Evans DGR. 1998. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NT2 and sporadic vestibular schwannomas. J Med Genet (in press).
39. Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL. 1994. Higher frequency of alterations in the CDKN2A/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053.